Molecular profiling of cancer - The future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 173-185

  Stricker, Thomas ^a,b   Catenacci, Daniel V T ^a   Seiwert, Tanguy Y ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MC2215 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CANCER GENETICS; CYTOGENETICS; DIAGNOSTIC TEST; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; HUMAN; INDEL MUTATION; LETHALITY; ONCOGENE; PHYSICIAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SCIENTIST; SYSTEMS BIOLOGY; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CLINICAL TRIALS AS TOPIC; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA REPAIR; GENE FUSION; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; ONCOGENES; SYSTEMS BIOLOGY;

EID: 79952943956     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.013     Document Type: Article

References (77)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. A. Jemal, M.M. Center, C. DeSantis, and E.M. Ward Global patterns of rd and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 2010 1893 1907
3. R. Nasr, M.C. Guillemin, and O. Ferhi Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation Nat Med 14 2008 1333 1342
4. G. Barbany, M. Hoglund, and B. Simonsson Complete molecular remission in chronic myelogenous leukemia after imatinib therapy N Engl J Med 347 2002 539 540 (Pubitemid 34879349)
5. G.N. Hortobagyi Trastuzumab in the treatment of breast cancer N Engl J Med 353 2005 1734 1736 (Pubitemid 41464714)
6. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743 (Pubitemid 46021510)
7. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
8. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
9. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
10. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
11. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
12. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566 (Pubitemid 47206930)
13. A. Jimeno, W.A. Messersmith, F.R. Hirsch, W.A. Franklin, and S.G. Eckhardt KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection J Clin Oncol 27 2009 1130 1136
14. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
15. A. Lievre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379 (Pubitemid 351171687)
16. D.J. Sargent, S. Marsoni, and G. Monges Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol 28 2010 3219 3226
17. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)
18. W. Schroth, M.P. Goetz, and U. Hamann Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 2009 1429 1436
19. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
20. G.R. Bignell, C.D. Greenman, and H. Davies Signatures of mutation and selection in the cancer genome Nature 463 2010 893 898
21. P.C. Ng, and S. Henikoff SIFT: predicting amino acid changes that affect protein function Nucleic Acids Res 31 2003 3812 3814 (Pubitemid 37442253)
22. T. Huang, P. Wang, and Z.Q. Ye Prediction of deleterious non-synonymous SNPs based on protein interaction network and hybrid properties PLoS One 5 2010 e11900
23. A. Torkamani, and N.J. Schork Identification of rare cancer driver mutations by network reconstruction Genome Res 19 2009 1570 1578
24. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res 68 2008 3077 3080
25. S.V. Sharma, M.A. Fischbach, D.A. Haber, and J. Settleman "Oncogenic shock": explaining oncogene addiction through differential signal attenuation Clin Cancer Res 12 2006 4392s 4395s (Pubitemid 44197187)
26. S. Jones, X. Zhang, and D.W. Parsons Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
27. Y. Bang, E. Kwak, and L. Shaw Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 18s (suppl; abstract 3)
28. G.F. Fleming, M.W. Sill, and K.M. Darcy Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 15 20
29. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
30. E.W. Joseph, C.A. Pratilas, and P.I. Poulikakos The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc Natl Acad Sci U S A 107 2010 14903 14908
31. J.D. Iglehart, and D.P. Silver Synthetic lethalitya new direction in cancer-drug development N Engl J Med 361 2009 189 191
32. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
33. A.M. Gonzalez-Angulo, B.T. Hennessy, and G.B. Mills Future of personalized medicine in oncology: a systems biology approach J Clin Oncol 28 2010 2777 2783
34. B.T. Hennessy, A.M. Gonzalez-Angulo, M.S. Carey, and G.B. Mills A systems approach to analysis of molecular complexity in breast cancer Clin Cancer Res 15 2009 417 419
35. The Cancer Genome Atlas http://cancergenome.nih.gov/about/index.asp
36. Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
37. I. Khalil, M.A. Brewer, T. Neyarapally, and C.D. Runowicz The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer Gynecol Oncol 116 2010 282 285
38. R.G. Verhaak, K.A. Hoadley, and E. Purdom Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
39. H. Noushmehr, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
40. S. Shete, F.J. Hosking, and L.B. Robertson Genome-wide association study identifies five susceptibility loci for glioma Nat Genet 41 2009 899 904
41. M. Wrensch, R.B. Jenkins, and J.S. Chang Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility Nat Genet 41 2009 905 908
42. H. Zheng, H. Ying, and R. Wiedemeyer PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas Cancer Cell 17 2010 497 509
43. H. Zheng, H. Ying, and H. Yan p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation Nature 455 2008 1129 1133
44. T.J. Hudson, W. Anderson, and A. Artez International network of cancer genome projects Nature 464 2010 993 998
45. C.A. Maher, C. Kumar-Sinha, and X. Cao Transcriptome sequencing to detect gene fusions in cancer Nature 458 2009 97 101
46. C.A. Maher, N. Palanisamy, and J.C. Brenner Chimeric transcript discovery by paired-end transcriptome sequencing Proc Natl Acad Sci U S A 106 2009 12353 12358
47. P.E. Barker Double minutes in human tumor cells Cancer Genet Cytogenet 5 1982 81 94 (Pubitemid 12165062)
48. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
49. W.C. Gustafson, and W.A. Weiss Myc proteins as therapeutic targets Oncogene 29 2010 1249 1259
50. R. Beroukhim, C.H. Mermel, and D. Porter The landscape of somatic copy-number alteration across human cancers Nature 463 2010 899 905
51. D. Gu, W.A. Scaringe, and K. Li Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature Hum Mutat 28 2007 760 770 (Pubitemid 47282437)
52. L.A. Saddic, L.E. West, and A. Aslanian Methylation of the retinoblastoma tumor suppressor by SMYD2 J Biol Chem 285 2010 37733 37740
53. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 2003 8418 8423 (Pubitemid 36842560)
54. I.S. Lossos, D.K. Czerwinski, and A.A. Alizadeh Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes N Engl J Med 350 2004 1828-17
55. A. Rosenwald, G. Wright, and W.C. Chan The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 2002 1937 1947 (Pubitemid 34651353)
56. F. Bertucci, N. Cervera, and D. Birnbaum A gene signature in breast cancer N Engl J Med 356 2007 1887 1888
57. R. Liu, X. Wang, and G.Y. Chen The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 2007 217 226 (Pubitemid 46143225)
58. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009 (Pubitemid 35461656)
59. M.L. Gatza, J.E. Lucas, and W.T. Barry A pathway-based classification of human breast cancer Proc Natl Acad Sci U S A 107 2010 6994 6999
60. J.T. Chang, C. Carvalho, and S. Mori A genomic strategy to elucidate modules of oncogenic pathway signaling networks Mol Cell 34 2009 104 114
61. M.M. Le Beau, C.A. Westbrook, M.O. Diaz, J.D. Rowley, and M. Oren Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia Nature 316 1985 826 828 (Pubitemid 15003743)
62. J.D. Rowley A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293 (letter)
63. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
64. T. Winder, and H.J. Lenz Beyond KRAS: a new approach in metastatic colorectal cancer Lancet Oncol 11 2010 706 707
65. L.E. MacConaill, C.D. Campbell, and S.M. Kehoe Profiling critical cancer gene mutations in clinical tumor samples PLoS One 4 2009 e7887
66. D. Dias-Santagata, S. Akhavanfard, and S.S. David Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Mol Med 2 2010 146 158
67. M. Meyerson, S. Gabriel, and G. Getz Advances in understanding cancer genomes through second-generation sequencing Nat Rev Genet 11 2010 685 696
68. M.L. Metzker Sequencing technologiesthe next generation Nat Rev Genet 11 2010 31 46
69. S.B. Ng, E.H. Turner, and P.D. Robertson Targeted capture and massively parallel sequencing of 12 human exomes Nature 461 2009 272 276
70. P.C. Ng, and S. Henikoff Predicting deleterious amino acid substitutions Genome Res 11 2001 863 874 (Pubitemid 32447869)
71. Z.A. Wainberg, A. Anghel, and A.J. Desai Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo Clin Cancer Res 16 2010 1509 1519
72. N.J. Nelson Adaptive clinical trial design: has its time come? J Natl Cancer Inst 102 2010 1217 1218
73. E.S. Kim, R.S. Herbst, and J.J. Lee The BATTLE trial (Biomarker- integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer AACR Annual Meeting 2010 Plenary Session, LB-1
74. S.J. Mandrekar, and D.J. Sargent Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 2009 4027 4034
75. M.A. Hamburg, and F.S. Collins The path to personalized medicine N Engl J Med 363 2010 301 304
76. M. Ladanyi, and W. Pao Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond Mod Pathol 21 Suppl 2 2008 S16 S22
77. M.F. Ciaccio, J.P. Wagner, C.P. Chuu, D.A. Lauffenburger, and R.B. Jones Systems analysis of EGF receptor signaling dynamics with microwestern arrays Nat Methods 7 2010 148 155